Cerebrolysin vs PE-22-28
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: FPE 1070
Cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by EVER Neuro Pharma in Austria. It is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. Despite decades of use abroad, the human evidence remains genuinely contested.
Also: PE22-28, Spadin Analog
PE-22-28 is a seven-amino-acid peptide that blocks a potassium channel in the brain called TREK-1, the same target tied to depression. It is a shortened, more potent and more stable version of spadin, a natural fragment cut from the sortilin propeptide, and it was built to act like a fast antidepressant. All evidence is from rodents. There are no human clinical trials.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Cerebrolysin has stronger research evidence (Human Trials) compared to PE-22-28 (Animal Studies).
Detailed Comparison
| Attribute | Cerebrolysin | PE-22-28 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The proposed idea is that Cerebrolysin's small peptides act like the body's own neurotrophic factors, the molecules such as BDNF and NGF that help neurons survive, grow, and form connections. Researchers hypothesize it engages neurotrophic signaling pathways and may protect neurons from injury and support repair after stroke or brain trauma. It is important to be clear that the exact active components and mechanism are not fully defined, partly because it is a complex biological mixture rather than one purified molecule. So the neurotrophic-mimic story is a plausible hypothesis supported by some lab data, not a precisely mapped pathway. | PE-22-28 inhibits TREK-1, a two-pore-domain potassium channel that normally lets potassium leak out of neurons and quiets them down. Block that leak and serotonin-producing neurons in mood-related regions become easier to fire, which is the proposed antidepressant mechanism. This is the same pathway implicated in why TREK-1 knockout mice show a depression-resistant phenotype. Compared to the parent peptide spadin, PE-22-28 binds TREK-1 far more tightly and survives much longer in the body, which is why it was developed. Whether TREK-1 blockade translates into a real antidepressant effect in people remains unproven. |
| Common Dosing | 20-32 mg/day subcutaneous (60mg vial reconstituted in 3 mL bac water = 20 mg/mL) Once or twice daily, split doses above 20 mg into AM/PM, gradual titration | 100-300 mcg intranasal or subcutaneous Once daily |
| Administration | Subcutaneous (research) or intravenous/intramuscular (clinical literature) | Intranasal or subcutaneous injection |
| Typical Duration | 8-16 week protocols for research-scale subQ; 10-20 day cycles for clinical IV | Research protocols vary, often 2-4 weeks |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Cerebrolysin has been tested in many human trials, but the quality and consistency of that evidence is the real story. A Cochrane systematic review on vascular dementia (Cui and colleagues, 2019) concluded that intravenous Cerebrolysin may improve cognition and global function, but cautioned the findings were not definitive because of high risk of bias and heterogeneity across studies. Cochrane reviews of acute ischemic stroke have similarly found insufficient or inconclusive evidence and have flagged a possible signal of increased non-fatal serious adverse events in some analyses. The Alzheimer's Drug Discovery Foundation's Cognitive Vitality review rates the human evidence as mixed and far from conclusive. So while it is a real, widely prescribed drug in many countries, the claim that it reliably improves brain outcomes is not established to Western regulatory standards, and many of the supporting trials come from a narrow set of investigators and sponsors. | The core data come from a single 2017 paper by Djillani and colleagues in Frontiers in Pharmacology, which screened shortened spadin analogs and found PE-22-28 to be the standout: dramatically stronger TREK-1 inhibition, longer in vivo stability, and antidepressant-like behavior in mice using standard tests like the forced swim and novelty-suppressed feeding paradigms. The same line of work reported that short treatment courses increased hippocampal neurogenesis in rodents, which the authors framed as a possible mechanism for faster mood effects than conventional SSRIs. The broader TREK-1 and spadin story traces back to Mazella et al. in 2010, who first described spadin as a natural antidepressant-type TREK-1 blocker. Importantly, every result is preclinical and in animals. There are no completed or published human efficacy or safety trials of PE-22-28, and it is not an approved drug anywhere. Claims that it treats depression, anxiety, or cognitive decline in people go well beyond what the evidence supports. |
Frequently Asked Questions: Cerebrolysin vs PE-22-28
What is the difference between Cerebrolysin and PE-22-28?
Cerebrolysin is a cognitive peptide that cerebrolysin is not a single peptide but a mixture: a preparation of small peptides and free amino acids made by enzymatically breaking down purified porcine (pig) brain protein, manufactured by ever neuro pharma in austria. it is given by injection and is approved as a prescription drug in dozens of countries for stroke, traumatic brain injury, and dementia, but it is not fda-approved in the united states. despite decades of use abroad, the human evidence remains genuinely contested. PE-22-28 is a cognitive peptide that pe-22-28 is a seven-amino-acid peptide that blocks a potassium channel in the brain called trek-1, the same target tied to depression. it is a shortened, more potent and more stable version of spadin, a natural fragment cut from the sortilin propeptide, and it was built to act like a fast antidepressant. all evidence is from rodents. there are no human clinical trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Cerebrolysin or PE-22-28?
Neither is universally "better" - the choice depends on your specific goals. Cerebrolysin is typically used for cognitive purposes, while PE-22-28 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Cerebrolysin and PE-22-28 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Cerebrolysin and PE-22-28 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.